ResultsIQ

ResultsIQ › Latest results › Aarti Pharmalabs Limited

Aarti Pharmalabs Limited Q2 FY27 earnings call summary

NSE: AARTIPHARM · BSE: 543748

Earnings call of 29 Oct 2026, summarised by AI from the filing.

Aarti Pharmalabs posted record Q2 FY27 revenue of ₹613 cr with EBITDA of ₹136 cr, and maintained 40% to 50% CDMO growth guidance for the year.

Key takeaways

  1. CDMO guidance CDMO/CMO revenue growth of 40% to 50% over last year maintained for this year.
  2. Steroid block Steroid block expansion completed and contributing to production and revenue, restoring API sales constrained in Q1.
  3. Raw material costs Elevated raw material costs from geopolitical turmoil are being passed on, with some EBITDA erosion.

Original filing on BSE

Aarti Pharmalabs Limited Q2 FY27 results

As filed: Revenue ₹610 cr (+46% year on year), EBITDA ₹135 cr (+80% year on year), PAT ₹71.5 cr (+155% year on year), EBITDA margin 22.1% (+420 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹536 cr (+39% year on year), EBITDA ₹136 cr (+43% year on year), PAT ₹76.1 cr (+52% year on year), EBITDA margin 25.4% (+79 bps). Score 82 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 79 bps year on year. Revenue fell 8% from last quarter. Share price after the results: +25.2% in 28 days (Nifty 500: −1.9%).
  • Q4 FY26: Revenue ₹583 cr (+3% year on year), EBITDA ₹113 cr (−23% year on year), PAT ₹61.1 cr (−31% year on year), EBITDA margin 19.4% (−665 bps). Score 42 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 665 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −3.1% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹432 cr (−20% year on year), EBITDA ₹102 cr (−21% year on year), PAT ₹48.0 cr (−35% year on year), EBITDA margin 23.7% (−31 bps). Score 22 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 31 bps year on year. Share price after the results: −14.3% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹418 cr (−9% year on year), EBITDA ₹75.0 cr (−21% year on year), PAT ₹28.0 cr (−49% year on year), EBITDA margin 17.9% (−280 bps). Score 17 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 280 bps year on year. Profit fell 44% from last quarter. Share price after the results: −16.2% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹386 cr (−30% year on year), EBITDA ₹95.0 cr (−2% year on year), PAT ₹50.0 cr (−9% year on year), EBITDA margin 24.6% (+713 bps). Score 19 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin rose 713 bps year on year. Revenue fell 32% from last quarter. Share price after the results: +6.6% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹564 cr (+11% year on year), EBITDA ₹147 cr (+25% year on year), PAT ₹88.0 cr (+35% year on year), EBITDA margin 26.1% (+274 bps). Score 51 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was above it. EBITDA margin rose 274 bps year on year. Share price after the results: +19.0% in 30 days (Nifty 500: +7.6%).
  • Q3 FY25: Revenue ₹538 cr (+20% year on year), EBITDA ₹129 cr (+34% year on year), PAT ₹74.0 cr (+40% year on year), EBITDA margin 24.0% (+260 bps). Score 78 of 100, Above trend. EBITDA margin rose 260 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Aarti Pharmalabs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.